News

Facts

25. August, 2023

New findings supporting CT001

Based on new findings in a 2023 meta-analysis by Fjendbo Galili et al., which...

Read more

Releases

24. August, 2023

Second quarter report Q2-2023

US co-development and commercialization partnership signed for CT001 – potential income already from 2024...

Read more

Releases

27. June, 2023

Cessatech and Ventis Pharma announce US partnership for CT001

On 27 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company...

Read more

Releases

12. May, 2023

First quarter report Q1-2023 with Q&A

First quarter report Q1-2023 Study 0205 is progressing, with last patient expected in Q3...

Read more

Releases

23. March, 2023

Cessatech announces new Chairman of the Board

On 23 March 2023 Cessatech A/S announces that the Board of Directors has appointed...

Read more

Releases

28. February, 2023

Annual Report for the fiscal year 2022

Cessatech today publishes its annual report for the fiscal year 2022, which also includes...

Read more

Media

11. February, 2023

Massive presence of off-label medicines in Danish neonatal departments

A nationwide survey using national hospital purchase data. Overall, off-label medication was widespread covering...

Read more

Releases

18. November, 2022

Third quarter report Q3-2022

Cessatech today releases its results for the period 1 July – 30 September 2022....

Read more

Releases

14. November, 2022

Successful outcome of Rights issue

The results of the rights issue announced on October 19, 2022 for which the...

Read more

Releases

19. October, 2022

DKK 18.3 million capital raise through a 80% guarantee

DKK 18.3 MILLION CAPITAL RAISE THROUGH A 80% GUARANTEED RIGHTS ISSUE TO FINANCE PIVOTAL...

Read more

Releases

23. September, 2022

Successful outcome of pharmacokinetic trial in children of lead candidate

Cessatech A/S announces positive topline outcome of its Phase 2 pharmacokinetics trial with CT001...

Read more

Releases

5. September, 2022

First patient dosed in pivotal trial of lead product candidate

First patient has been dosed in pivotal trial of lead candidate CT001 The pivotal...

Read more

Stay up to date!

Subscribe and get notified on Cessatech's latest news.
An acceptance email will be sent to you, please check your spam.